Pharnext Announces the Apppointment of Peter Collum as Chief Financial Officer and Chief Business Officer

Pharnext 
Pharnext Announces the Apppointment of Peter Collum as Chief Financial Officer and 
Chief Business Officer 
 
26-Jun-2019 / 08:00 CET/CEST 
Dissemination of a French Regulatory News, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
 
*Pharnext Announces the Apppointment of Peter Collum* 
*as Chief Financial Officer and Chief Business Officer* 
 
*PARIS, France, 8:00 am, 26 June 2019 (CEST) - *Pharnext SA [1]*(FR0011191287 - 
ALPHA)*, a biopharmaceutical company pioneering a new approach to developing 
innovative drug combinations based on genomic big data and artificial intelligence, 
today announced the appointment of Peter Collum as Chief Financial Officer and Chief 
Business Officer. 
_"We are very excited to welcome Peter to our team," _said *Daniel Cohen, M.D., Ph.D., 
Pharnext's Co-Founder and Chief Executive Officer. *_"Peter's deep financial acumen 
alongside his in-depth business development expertise will make him a great asset to 
our team. We look forward to_ _Peter's insights and contributions as we progress our 
PLEOTHERAPY programs through late-stage development"._ 
 
Mr. Collum joins Pharnext with over 17 years of experience in healthcare investment 
banking, focused on M&A, financing and business development transactions. Prior to 
joining Pharnext, Mr. Collum was a Partner at MTS Health Partners, a boutique 
healthcare investment bank in New York, NY, where he worked closely with Pharnext for 
almost 5 years and is well versed with its financial, technological, R & D and 
regulatory aspects. During his 10 years at the firm, Mr. Collum led and participated 
in numerous M&A and financing deals for public and private life sciences companies 
both in the US and abroad. Previously, he worked in the healthcare investment banking 
group at Bank of America, with a focus on life sciences. Mr. Collum started his career 
at Roche as an engineer. He holds an M.B.A. from the Booth School of Business at the 
University of Chicago and a B.S. from Rutgers University College of Engineering. 
 
"_It's an incredible opportunity to join Pharnext at such an exciting time_," said Mr. 
Collum. "_PLEOTHERAPY discovery platform has great potential across a range of rare 
and common diseases, and I look forward to joining the executive team as Pharnext 
continues to grow as a biopharma company._" 
 
*About Pharnext* 
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel 
therapeutics for orphan and common neurodegenerative diseases that currently lack 
curative and/or disease-modifying treatments. Pharnext has two lead products in 
clinical development. PXT3003 completed an international Phase 3 trial with positive 
topline results for the treatment of Charcot-Marie-Tooth disease type 1A and benefits 
from orphan drug status in Europe and the United States. PXT864 has generated 
encouraging Phase 2 results in Alzheimer's disease. Pharnext has developed a new drug 
discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY. 
Pharnext identifies and develops synergic combinations of drugs called PLEODRUG. The 
Company was founded by renowned scientists and entrepreneurs including Professor 
Daniel Cohen, a pioneer in modern genomics, and is supported by a world-class 
scientific team. 
Pharnext is listed on the Euronext Growth Stock Exchange in Paris (ISIN code: 
FR0011191287). 
For more information, visit www.pharnext.com [1] 
 
*CONTACTS* 
*Pharnext* 
Xavier Paoli 
Chief Commercial 
Officer 
[e-mail] 
[phone] 
*Financial Communication      *Investor Relations       *Investor Relations 
(France)*                     (U.S.)*                   (Europe)* 
Actifin                       Stern Investor            MC Services AG 
Stéphane Ruiz                 Relations, Inc.           Anne Hennecke 
[e-mail]              Jane Urheim               [e-mail] 
[phone]          [e-mail]   [phone] 
                              [phone] 
*Media Relations (Europe)*    *Media Relations (U.S.)* 
Ulysse Communication          RooneyPartners 
Bruno Arabian                 Kate L. Barrette 
barabian                      [e-mail] 
[2]@ulysse-communication.com  [phone] 
[phone] 
 
_Disclaimer _ 
This press release contains certain forward-looking statements concerning Pharnext and 
its business. Such forward-looking statements are based on assumptions that Pharnext 
considers to be reasonable. However, there can be no assurance that the estimates 
contained in such forward-looking statements will be verified, which estimates are 
subject to numerous risks including the risks set forth in Pharnext's document de base 
filed with the AMF on June 2, 2016 under number I.016-0050 as well as in any other 
periodic report and in any other press release (a copy of which is available on 
www.pharnext.com) and to the development of economic conditions, financial markets and 
the markets in which Pharnext operates. The forward-looking statements contained in 
this press release are also subject to risks not yet known to Pharnext or not 
currently considered material by Pharnext. The occurrence of all or part of such risks 
could cause actual results, financial conditions, performance or achievements of 
Pharnext to be materially different from such forward-looking statements. Pharnext 
disclaims any intention or obligation to publicly update or revise any forward-looking 
statements, whether as a result of new information, future events, or otherwise. 
_This press release and the information that it contains do not constitute an offer to 
sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, 
Pharnext shares in any country._ 
 
Regulatory filing PDF file 
 
Document title: Pharnext Announces the Apppointment of Peter Collum as Chief Financial 
Officer and Chief Business Officer 
Document: http://n.eqs.com/c/fncls.ssp?u=OCWYXGCCUD [3] 
830883 26-Jun-2019 CET/CEST 
 
 
1: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=cb3681285800d269b63272738266ab82&application_id=830883&site_id=vwd&application_name=news 
2: mailto:[e-mail] 
3: https://link.cockpit.eqs.com/cgi-bin/fncls.ssp?fn=redirect&url=137b09c1e88536986b28bc370f73ec44&application_id=830883&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

June 26, 2019 02:00 ET (06:00 GMT)